Leslie Amass

4.2k total citations
65 papers, 2.9k citations indexed

About

Leslie Amass is a scholar working on Molecular Biology, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Leslie Amass has authored 65 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 24 papers in Epidemiology and 20 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Leslie Amass's work include Amyloidosis: Diagnosis, Treatment, Outcomes (28 papers), Opioid Use Disorder Treatment (20 papers) and Substance Abuse Treatment and Outcomes (17 papers). Leslie Amass is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (28 papers), Opioid Use Disorder Treatment (20 papers) and Substance Abuse Treatment and Outcomes (17 papers). Leslie Amass collaborates with scholars based in United States, Brazil and Germany. Leslie Amass's co-authors include Warren K. Bickel, Jonathan B. Kamien, Gary J. Badger, Stephen T. Higgins, Hartmut Schmidt, Márcia Waddington‐Cruz, Isabel Conceição, Susan K. Mikulich, Stephen T. Higgins and Alejandra González‐Duarte and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Leslie Amass

64 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leslie Amass United States	30	1.3k	1.2k	895	389	385	65	2.9k
Beth A. Bailey United States	30	403 0.3×	449 0.4×	587 0.7×	94 0.2×	651 1.7×	131	2.7k
D. Andrew Tompkins United States	25	696 0.5×	420 0.4×	229 0.3×	336 0.9×	257 0.7×	49	1.9k
Javier Ballesteros Spain	29	422 0.3×	382 0.3×	343 0.4×	393 1.0×	223 0.6×	118	2.7k
Jacquelyn L. Meyers United States	26	234 0.2×	526 0.5×	354 0.4×	423 1.1×	170 0.4×	75	3.1k
Veronica Collins Australia	32	485 0.4×	319 0.3×	763 0.9×	66 0.2×	481 1.2×	69	3.1k
V. P. Prasher United Kingdom	28	1.5k 1.2×	618 0.5×	292 0.3×	88 0.2×	139 0.4×	94	2.6k
Iqbal Ike K. Ahmed Canada	48	1.2k 0.9×	603 0.5×	346 0.4×	117 0.3×	69 0.2×	288	8.3k
Andrew J. Levine United States	27	210 0.2×	522 0.4×	553 0.6×	64 0.2×	186 0.5×	94	3.3k
Jakob Grove Denmark	32	355 0.3×	316 0.3×	470 0.5×	89 0.2×	765 2.0×	93	2.8k

Countries citing papers authored by Leslie Amass

Since Specialization

Citations

This map shows the geographic impact of Leslie Amass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leslie Amass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leslie Amass more than expected).

Fields of papers citing papers by Leslie Amass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leslie Amass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leslie Amass. The network helps show where Leslie Amass may publish in the future.

Co-authorship network of co-authors of Leslie Amass

This figure shows the co-authorship network connecting the top 25 collaborators of Leslie Amass. A scholar is included among the top collaborators of Leslie Amass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leslie Amass. Leslie Amass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Amass, Leslie, et al.. (2024). Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy. Cardiology and Therapy. 13(2). 359–368.

García‐Pavía, Pablo, Arnt V. Kristen, Brian Drachman, et al.. (2024). Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS). Journal of Cardiac Failure. 31(3). 525–533. 13 indexed citations

Gentile, Luca, Igor Diemberger, Violaine Planté‐Bordeneuve, et al.. (2024). Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS). PLoS ONE. 19(1). e0292435–e0292435. 2 indexed citations

Samjoo, Imtiaz A., et al.. (2020). The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy. Current Medical Research and Opinion. 36(5). 799–808. 4 indexed citations

González‐Duarte, Alejandra, Isabel Conceição, Leslie Amass, et al.. (2020). Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy. Neurology and Therapy. 9(1). 135–149. 6 indexed citations

Schmidt, Hartmut, Márcia Waddington‐Cruz, Marc Botteman, et al.. (2016). Global Prevalence Estimates of Transthyretin Familial Amyloid Polyneuropathy (ATTR-FAP): A Systematic Review and Projections. Value in Health. 19(7). A601–A601. 1 indexed citations

Amass, Leslie, Emilis Subata, Maria Pieri, et al.. (2011). A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin‐dependent individuals. Addiction. 107(1). 142–151. 24 indexed citations

Comer, Sandra D., Maria A. Sullivan, Suzanne K. Vosburg, et al.. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusers. Addiction. 105(4). 709–718. 83 indexed citations

Kamien, Jonathan B., Steven A. Branstetter, & Leslie Amass. (2008). Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients. 10(4). 5–18. 33 indexed citations

10.

Kamien, Jonathan B., et al.. (2007). Two-year Experience with Buprenorphine-naloxone (Suboxone) for Maintenance Treatment of Opioid Dependence Within a Private Practice Setting. Journal of Addiction Medicine. 1(2). 104–110. 34 indexed citations

11.

Branstetter, Steven A., et al.. (2007). A history of sexual, emotional, or physical abuse predicts adjustment during opioid maintenance treatment. Journal of Substance Abuse Treatment. 34(2). 208–214. 29 indexed citations

12.

Reback, Cathy J., Jonathan B. Kamien, & Leslie Amass. (2006). Characteristics and HIV risk behaviors of homeless, substance-using men who have sex with men. Addictive Behaviors. 32(3). 647–654. 28 indexed citations

13.

Amass, Leslie, Walter Ling, Thomas E. Freese, et al.. (2004). Bringing Buprenorphine‐Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience. American Journal on Addictions. 13(S1). S42–66. 125 indexed citations

14.

Amass, Leslie & Jonathan B. Kamien. (2004). A Tale of Two Cities: Financing Two Voucher Programs for Substance Abusers Through Community Donations.. Experimental and Clinical Psychopharmacology. 12(2). 147–155. 34 indexed citations

15.

Amass, Leslie, Jonathan B. Kamien, & Susan K. Mikulich. (2000). Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine–naloxone tablet. Drug and Alcohol Dependence. 58(1-2). 143–152. 108 indexed citations

16.

Bickel, Warren K., et al.. (1999). Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology. 146(2). 111–118. 85 indexed citations

17.

Moody, David E., Dennis J. Crouch, R. L. Foltz, et al.. (1997). Determination of Buprenorphine in Human Plasma by Gas Chromatography-Positive Ion Chemical Ionization Mass Spectrometry and Liquid Chromatography-Tandem Mass Spectrometry. Journal of Analytical Toxicology. 21(6). 406–414. 59 indexed citations

18.

Amass, Leslie, Warren K. Bickel, Stephen T. Higgins, & Gary J. Badger. (1994). Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sciences. 54(17). 1215–1228. 79 indexed citations

19.

Lukas, S E, Richard A. Benedikt, Jack H. Mendelson, et al.. (1992). Marihuana attenuates the rise in plasma ethanol levels in human subjects.. PubMed. 7(1). 77–81. 35 indexed citations

20.

Amass, Leslie, Rachel Nardin, Jack H. Mendelson, S K Teoh, & Bryan T. Woods. (1992). Quantitative magnetic resonance imaging in heroin- and cocaine-dependent men: A preliminary study. Psychiatry Research Neuroimaging. 45(1). 15–23. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact